Company Overview

Positron Corporation is a U.S.-based medical technology company operating in the medical imaging and diagnostic equipment industry, with a primary focus on positron emission tomography (PET) solutions for cardiology. The company designs, manufactures, and services PET imaging systems used primarily for the non-invasive detection and management of cardiovascular disease. Its core value proposition centers on providing lower-cost, dedicated cardiac PET systems aimed at improving diagnostic accuracy and operational efficiency for outpatient imaging centers, hospitals, and cardiology practices.

The company’s principal revenue drivers include the sale of PET imaging systems, related upgrades, extended service and maintenance contracts, and software enhancements. Positron positions itself as a niche provider specializing in cardiac PET rather than whole-body PET/CT systems, which are dominated by larger multinational competitors. Founded in 1992, the company originally pursued nuclear medicine technologies and later narrowed its strategic focus to cardiac PET imaging following multiple restructurings, recapitalizations, and product realignments over its operating history.

Business Operations

Positron operates primarily through its core business unit, Positron Medical Imaging, which encompasses system design, manufacturing oversight, installation, training, and lifecycle service support. The company generates revenue through capital equipment sales of its PET imaging systems, recurring service agreements, and customer upgrades. Manufacturing is largely outsourced, while engineering, system integration, regulatory compliance, and customer support are managed internally.

Operations are predominantly domestic within the United States, with limited international sales activity conducted through distributors rather than owned foreign subsidiaries. The company controls proprietary system designs and software specific to cardiac PET workflows but does not own radiopharmaceutical production assets. Public disclosures indicate no material joint ventures; however, Positron maintains commercial relationships with imaging centers, cardiology groups, and component suppliers critical to system assembly and deployment.

Strategic Position & Investments

Positron’s strategic direction emphasizes expanding adoption of cardiac PET as a preferred diagnostic modality for coronary artery disease, particularly in outpatient and non-hospital settings. Growth initiatives have focused on upgrading its PET platform, expanding service contract penetration, and pursuing regulatory-cleared enhancements designed to improve image quality, throughput, and total cost of ownership for customers.

The company has historically relied on incremental internal development rather than large-scale acquisitions. Public filings do not indicate ownership of a diversified subsidiary portfolio or significant equity investments in unrelated businesses. Positron’s strategy is centered on maintaining a specialized market position rather than competing directly with large diversified imaging manufacturers. Data regarding material investments in emerging technologies beyond cardiac PET is inconclusive based on available public sources.

Geographic Footprint

Positron Corporation is headquartered in the United States, and its operational footprint is primarily domestic. The majority of customers, revenue, and installed systems are located within U.S. cardiology practices, imaging centers, and hospitals. Sales, service, and regulatory activities are structured around U.S. healthcare reimbursement and compliance frameworks.

International presence is limited and generally indirect, with occasional system placements outside the United States facilitated through third-party distributors. Public disclosures do not show a significant operational footprint in Europe, Asia-Pacific, or other global regions, nor material international manufacturing or research facilities.

Leadership & Governance

Positron is led by an executive team with experience in medical imaging, healthcare operations, and public company management. The company operates with a lean leadership structure typical of small-cap medical device firms, with executives often holding multiple operational responsibilities. Strategic vision communicated in public filings emphasizes disciplined cost management, clinical differentiation in cardiac PET, and long-term shareholder value creation.

Key executives disclosed in recent public filings include:

• Joe Oliverio – President and Chief Executive Officer
• Dana Posner – Chief Financial Officer (title and tenure based on public disclosures; details may vary by reporting period)
• David Smith – Chief Technology Officer (role based on historical filings; current status data inconclusive based on available public sources)

Information regarding board composition, committee structure, and executive tenure is derived from company regulatory filings; however, certain role changes and governance details may not be consistently updated across all public sources, and some data remains inconclusive.